Introduction
Ovarian cancer accounts for the highest tumor related mortality among gynecologic malignancies and is the fifth most frequent cause of cancer related death. In 2014, the incidence rate for women in developed countries was about 9.4 per 100,000 compared to 5.0 per 100,000 in developing countries. However, approximately 25% of cases are diagnosed between ages 35 and 54 (Jayson et al., 2014) . Above 70% of women were diagnosed with late stage III and IV disease.
Although not withstanding great advancements have been made in the treatments and management control of the cancer progression. A number of undesired adverse effects, sometimes, occurs during chemotherapy (Desai et al., 2008) . Research reports suggest that compounds from natural sources are superior to synthetic compounds in terms of pharmacokinetic and pharmacodynamics properties.
In general, usage of medicinal compounds is always superior to the synthetic compounds. So, the recent research has been focused towards the plant compound isolation and compounds production at large scale (Fortes et al., 2012) .
A large proportion of the World population depends on the traditional medicine because of the shortage and high expenses of orthodox medicine (Dutta and Maharia, 2012; Li et al., 2011; Sultana et al., 2011) . Natural products play a central role in the development of novel drug for the treatment and prevention of diseases (Khan et al., 2015; Sharma et al., 2015; Yu et al., 2013; Dhanamani et al., 2011) . yellow waxy oil, steroids, terpenoids, flavonoids and tannins . The whole plant is used as a diuretic, in tumors, neuralgia and splenopathy. The bark extract has been reported to have antiviral, antibacterial, anti-protozoal, hypoglycemic, anti-cancer and diuretic activities in animal models (Gupta et al., 2012) . So far against ovarian cancer, the bioactive compounds have not been isolated from this plant. Therefore, the purpose of the present study is to isolate and identify the potent anti-ovarian cancer compound from C. trifolia by using experimental models and to establish the possible real value of these kinds of compounds as anti-ovarian cancer agents. The steps of fractionation, purification and structure elucidation are basically required to characterize the plant based compounds. Computational molecular simulation studies will be conducted to study the molecular interactions of bioactive compound (ligand) with ovarian cancer target proteins and to validate the potential binding mode. These studies provide excellent prediction on possible mechanism of action of the experimentally studied compound.
Materials and Methods

Collection of plant and authentication
The whole plant of C. trifolia was collected from in and around the area of Poonthottam (Kumbakonam Town), Tamil Nadu, India and it was authenticated by Dr. P. Sathyanarayanan, Botanical Survey of India, TNAU Campus, Coimbatore. The voucher number of the plant was BSI/SRC/5/23/2010-2011/Tech.1527. The fresh material of the whole plant was washed under the running tap-water, dipped in saline overnight, air dried and then pulverized. The fine powder obtained from the procedure was used in the present study .
Extract preparation
Based on the previous studies, 300 g of dried plant powder was extracted in 1,500 mL of ethanol in a sporadic shaker for 72 hours at room temperature. The extract was collected and kept concentrated at 40°C under reduced pressure using rotary evaporator. The dried extract was stored at 4°C until further compound isolation process.
Compound isolation
Ethanolic extract of the C. trifolia (5 g) was subjected to purification on silica gel column (3 × 30 cm) and various fractions were successfully eluted with petroleum ether (100%) followed by a ratio of petroleum ether: chloroform (8:2, 6:4, 4:4, 2:8 v/v). The column fractions were collected in 20 mL test tubes. Totally 52 fractions were collected from the silica gel column and these fractions were loaded on the activated silica gel TLC plates (20 × 20 cm). The plates were developed using petroleum ether: chloroform (90:10), chloroform: ethyl acetate (90:10) and ethyl acetate: methanol (90:10) solvents. The single spot was located by exposing the plate to iodine fumes.
Structure elucidation
The isolated bioactive compound was crystallized in alcoholic medium using slow evaporation method at room temperature. The intensity data were collected using Bruker Smart apex II single crystal X-Ray diffractometer equipped with CCD available in CAS in Crystallography and Biophysics, The University of Madras. The structures were solved by direct methods using the program SHELXS-97 (Cremer and Pople, 1975) and refined by full-matrix least-squares procedures using the program SHELXL-97 inbuilt in WinGX software (Sheldrick, 2008) . The geo-metrical parameters were calculated using the program PARST and graphical plots were drawn using the programs ORTEP-3 (Farrugia, 2012) and PLATON (Spek, 2009 ).
In silico studies on chemical molecules -protein targets interactions
Preparation of protein structure
The 3D structure of HER2, EGFR and CXCR4 were retrieved from the protein data bank (www.rcsb.org) and these proteins were prepared by protein preparation wizards (standard methods) that are available in grid-based ligand docking with energetics. Proteins were optimized using sample water orientation and minimized by using RMSD 0.30 Å and OPLS (2005) force field (Protein Preparation Wizard).
Active site prediction
The active sites (binding pockets) and functional residues of HER2, EGFR and CXCR4 were identified and characterized by Site-Map module from Schrodinger package (SiteMap version 3.3). SiteMap calculation begins with an initial search step that identifies or characterizes through the use of grid points-one or more regions on the protein surface that may be suitable for binding ligands to the receptor. Contour maps were then generated, produced hydrophobic, hydrophilic maps hydrogen binding possibilities which may guide the protein-ligand docking analysis.
Ligand preparation
Epifriedelanol and carboplatin were used in molecular docking studies. These ligands were prepared using LigPrep version 3.3.. The structure of each ligands were optimized by means of the OPLS 2005 force field using a default setting.
Molecular docking analysis
All docking analyses were performed by using the standard precision (SP) which is standard mode of Glide (Grid-based ligand docking with energetic) module from Glide version 6.6. Epifriedelanol and carboplatin ligands were docked to in the binding site of HER2, EGFR and CXCR4 using GLIDE. The scaling Vander Waals radii were 1.0 in the receptor grid generation. Grid was prepared with the bounding box set on 20Aº. The co-ordinates of this enclosing box with the help of the active site residues to be set default. The force field is used for the docking protocol is OPLS_2005. The lowest-energy docked complexes were found in the majority of similar docking conformations (Srinivasan et al., 2014) .
ADME properties prediction
Epifriedelanol and carboplatin (existing FDA approved drugs for ovarian cancer) were checked for their ADME properties using QikProp 4.3 module. QikProp helps in analyzing the pharmacokinetics and pharmacodynamics of the ligand by accessing the drug like properties. Predicted significant ADME properties are viz, Molecular weight, H-bond donor, H-bond acceptor and log P (o/w) (QikProp, version 4.3).
Results
Concentrated crude extract (5 g) was collected from the ethanolic extract of C. trifolia and it was fractionated with column chromatography. Through the column, 52 fractions were collected and analyzed by TLC plates. Out of 52 fractions, 13 th fraction showed single spot and it's formed as crystal (yielded crystal weight was 15 mg). The isolated crystal data retrieved from X-ray crystallography method (Table I ). In the crystal structure, all the five cyclohexane rings adopt a chair conformation (Figure 1 ).
The cyclohexane ring 1 (C1/C2/C3/C20/C21/C22) made a dihedral angle of 13.86 (1)° with the cyclohexane ring 2 (C3/C4/C5/C6/C19/C20); a dihedral angle of 28.22 (1) 0.32 and −0.25 graphy data, the isolated crystal structure was identified as epifriedelanol and it had been reported (NMR structure) to have in vitro antitumor properties in a potato disc bioassay study (Kundu et al., 2000) .
In docking results, the HER2-epifriedelanol complex had comparable good Glide score of -4.808 and Glide energy of -36.178 kcal/mol, when compared with HER2 -carboplatin complex which had Glide score of -4.802 and Glide energy of -17.098 kcal/mol. HER2-epifriedelanol complex had good affinity because of strong hydrogen bond formed between H atom and residue TYR281 within the complex. On the other hand, HER2-carboplatin complex also had comparable affinity through the hydrogen bonds between residue and atom of ASN37-O and GLN84-O respectively (Figure 2 ).
EGFR-epifriedelanol complex possessed comparable In the same way, EGFR-carboplatin complex also possess-ed good affinity, because of strong hydrogen bond that was formed between residues and atoms of C -O-GLN-81, GLU3, GLN59 and ARG231-C=O respectively (Figure 3 ).
CXCR4-epifriedelanol complex possessed good Glide score of -4.935 and Glide energy of -40.795 when compared with CXCR4-carboplatin complex whose Glide score and Glide energy were -4.540 and -16.907 kcal/ mol respectively. The epifriedelanol compound binded in hydrophobic region of CXCR4. On the other hand, in carboplatin compound C-O atom strongly bind with CXCR4 residue of TYR121 by the hydrogen bond (Figure 4 ). The ADME properties prediction result of epifriedelanol and carboplatin were under acceptable range.
Discussion
The phytochemical constituents of the plant extracts are the major basis of pharmacological activities of medicinal plants whereas flavonoids are anti-oxidants and minerals play significant roles in many processes taking place in living systems .
The active site (binding pocket/site) was preferred based on the site score and hydrophobic/hydrophilic areas, which holds better binding cavity. The binding site residues of HER2, EGFR and CXCR2 produced hydrophobic, hydrophilic maps and hydrogen binding possibilities which may guide the protein-ligand docking analysis (Tripathi et al., 2012) . In order to rationalize the described structure characterization, protein preparation and site map prediction results, molecular docking studies were undertaken on epifriedelanol (isolated compound) and carboplatin (FDA approved drug for ovarian cancer) complexes with X-Ray crystal structure of HER2, EGFR and CXCR2 (ovarian cancer targets). The molecular docking is frequently used to predict the binding orientation of small molecule drug candidate to their protein targets in order to predict the affinity and activity of the small molecule . The molecular docking performance indicated that, compared with FDA approved drug the isolated bioactive compound of epifriedelanol has better affinity with ovarian cancer targets. The limitations of ADME properties are: Not more than 5 hydrogen bond donors, Not more than 10 hydrogen bond acceptor, A molecular mass less than 500 daltons, An octanol-water partition coefficient log P not greater than 5. Thus, the ADME 
Conclusion
The isolated bioactive compound, epifriedelanol might act as a good inhibitor against ovarian cancer targets. 
